Rekvina Laboratories Ltd

Transaction details

• Target company: Rekvina Laboratories Limited.
• Disclosing party: Promoters Surbhit Mukesh Shah, Amit Mukesh Shah, Ami Amit Shah, Krima Surbhit Shah (promoter group).
• Transaction type: Acquisition of equity shares via open offer and preferential allotment.
• Pre-transaction voting rights: Surbhit Mukesh Shah 9,17,607; Amit Mukesh Shah 8,27,883; Ami 0; Krima 0.
• Post-transaction voting rights: Surbhit 30,17,427; Amit 30,17,426; Ami 3,33,845; Krima 3,33,843.
• Total post-voting rights: 67,02,541 (60.30%).
• Mode of acquisition: Open Offer and preferential allotment via share swap.
• Dates: August 12, 2026 (preferential allotment) and August 13, 2026 (open offer).
• Equity share capital before: 3,01,40,000.
• Equity share capital after: 5,55,78,750.
• Total diluted share capital after: 5,55,78,750.
• Note: Open Offer shares 5,43,570; Preferential Allotment 6,22,500.
• Note: Open Offer 8,293; Preferential Allotment 8,72,500.

Acquisition details

• Target: Rekvina Laboratories Limited.
• Acquirer: Dhruvalkumar Patel; PAC: Dhruvalkumar Patel.
• Promoter group: No.
• Exchange: BSE Limited.
• Pre-acquisition voting rights: Nil.
• Pre-acquisition encumbrances: Nil.
• VR other than shares: Nil.
• Warrants: Nil.
• Shares acquired: 11,12,562 voting rights (10.01%).
• Post-acquisition holding: 11,12,562 voting rights (10.01%).
• Mode: Open Offer under SAST; share swap via preferential allotment.
• Dates: August 12, 2026; August 13, 2026.
• Before capital: 60,28,000 shares of ₹5.
• Total pre-capital: ₹3,01,40,000.
• After capital: 1,11,15,750 shares of ₹5.
• Total post-capital: ₹5,55,78,750.
• Total diluted post-acquisition: 1,11,15,750 shares.
• Salient features: Consideration via share swap (non-cash).

Price movement clarification

• Company states no undisclosed price-sensitive information; movement is market-driven; all material events have been disclosed.

Key board actions

• Appointed Surbhit Shah as Executive Director and Chairman of the Board.
• Standalone unaudited results for the quarter ended 30 June 2026 approved.
• Limited Review Report on standalone results for the quarter ended 30 June 2026 approved.
• Audit Committee reviewed results; auditor issued an unmodified limited review report.

Financials

• Revenue from operations for quarter ended 30 June 2026: Rs 66.85 Lacs; net loss Rs 12.05 Lacs.
• Results prepared under IND AS 34; reviewed by Audit Committee and limited review completed.

Dematerialisation / rematerialisation status

• Dematerialisation requests processed; certificates accepted/rejected and confirmed to depositories.
• Securities dematerialised have been listed on the stock exchanges.
• Physical certificates for dematerialisation mutilated and cancelled after verification; depository's name substituted as registered owner.
• Actions completed within prescribed timelines.

Open Offer Overview

• Public open offer to Rekvina Laboratories' shareholders by Acquirers.
• Acquirers: Surbhit Mukesh Shah, Amit Mukesh Shah, Dhruvalkumar Patel.
• Trigger: Pre-Offer Advertisement under SEBI SAST.
• Target: Rekvina Laboratories Limited.

Offer Details

• Offer size, price, and period not disclosed in this chunk.
• Payment method not disclosed.
• Regulatory approvals not specified.
• Conditional/minimum acceptance not stated.
• No competing or revised offers indicated.

Key Dates

• Date: June 30, 2026.
• Open/close dates not provided.

Post-Offer Impact

• No post-offer ownership or float details provided.
• No delisting or asset sale intentions stated.

Board/Committee Recommendations

• No independent director recommendations included.

Financial Highlights

• No financials provided in this chunk.

Rekvina Laboratories Ltd: Trading window closure from July 01, 2026 until 48 hours after the declaration of Financial Results for the Quarter ended June 30, 2026

Meeting Details

• Board meeting scheduled for 21 May 2026.

Key Agenda Items

• Approve audited standalone financial results for quarter and year ended 31 March 2026.

Other Notes

• Trading window closed from 1 April 2026 until 48 hours after results are made public.